XML 83 R74.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Aug. 31, 2021
Jul. 31, 2021
Dec. 31, 2019
Apr. 30, 2017
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Klarity License Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payment in cash         $ 30,000 $ 35,000  
Royalty expense         71,000 35,000  
Klarity License Agreement [Member] | Richard L. Lindstrom, M.D [Member]              
Loss Contingencies [Line Items]              
Royalty payment description       Under the terms of the Klarity License Agreement, the Company is required to make royalty payments to Dr. Lindstrom ranging from 3% - 6% of net sales, dependent upon the final formulation of the Klarity Product sold      
Injectable Asset Purchase Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payment in cash         8,000 7,000  
Royalty expense         $ 7,000 7,000  
Injectable Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]              
Loss Contingencies [Line Items]              
Royalty payment description     the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 3% of net sales, dependent upon the final formulation and patent protection of the Lindstrom Product sold        
Initial milestone payment     $ 33,000        
Dexycu Agreement [Member]              
Loss Contingencies [Line Items]              
Commission expiration date         Aug. 01, 2025    
Commission revenues         $ 1,320,000 485,000  
Sales and Marketing Agreements [Member]              
Loss Contingencies [Line Items]              
Description for commission payments         Under the terms of the sales and marketing agreements, the Company is generally required to make commission payments equal to 10% - 14% of net sales for products above and beyond the initial existing sales amounts    
Commission expenses         $ 1,047,000,000 804,000,000  
Sales and Marketing Agreements [Member] | Minimum [Member]              
Loss Contingencies [Line Items]              
Commission payments percentage         10.00%    
Sales and Marketing Agreements [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Commission payments percentage         14.00%    
Asset Purchase, License and Related Agreements [Member]              
Loss Contingencies [Line Items]              
Royalty expense         $ 213,000 232,000  
Sintetica Agreement [Member]              
Loss Contingencies [Line Items]              
Payment for royalties   $ 18,000,000          
Sintetica Agreement [Member] | Research and Development Expense [Member]              
Loss Contingencies [Line Items]              
Payment for royalties             $ 3,117,000
Sintetica Agreement [Member] | Due Within Thirty Days [Member]              
Loss Contingencies [Line Items]              
Payment for royalties   $ 5,000,000          
Wakamoto Agreement [Member]              
Loss Contingencies [Line Items]              
Payment for royalties $ 2,000,000            
Commercial payments for royalties $ 6,200,000            
Presbyopia Asset Purchase Agreement [Member]              
Loss Contingencies [Line Items]              
Milestone payment in cash         0 0  
Royalty expense         0 0  
Milestone payments on payables         $ 0 $ 0  
Presbyopia Asset Purchase Agreement [Member] | Richard L. Lindstrom, M.D [Member]              
Loss Contingencies [Line Items]              
Royalty payment description     the Company is required to make royalty payments to Dr. Lindstrom ranging from 2% to 4% of net sales, dependent upon the final formulation and patent protection of the Presbyopia Product sold